Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk.

ABSTRACT:

Aims

Ticagrelor is associated with a lower risk of ischemic events than clopidogrel. However, it is uncertain whether the benefits of more intensive anti-ischemic therapy outweigh the risks of major bleeding in patients who have a high bleeding risk (HBR). Therefore, this study compared ticagrelor and clopidogrel in myocardial infarction (MI) patients with HBR.

Methods and results

This study included all patients enrolled in the SWEDEHEART registry who were discharged with dual antiplatelet therapy using ticagrelor or clopidogrel following MI between 2010 and 2017. High bleeding risk was defined as a PRECISE-DAPT score ≥25. Information on ischemic events, major bleeding, and mortality was obtained from national registries, with 365 days of follow-up. Additional outcomes incl

SUBMITTER: Tjerkaski J 

PROVIDER: S-EPMC10627816 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature